CLINICAL STUDY ON MEROPENEM

Meropenem (MEPM) was adiministered by intravenous drip infusion at 500 mg b.i.d. to four patients with respiratory tract infections for 3 to 14 days. The clinical responses were good in two and poor in one of the three cases of bacterial pneumonia and poor in one case of infected lung cancer. One st...

Full description

Saved in:
Bibliographic Details
Published inCHEMOTHERAPY Vol. 40; no. Supplement1; pp. 851 - 853
Main Authors Miki, Fumio, Tanizawa, Shinichi, Hiruma, Masahito, Ikuno, Yoshiyasu, Sakamoto, Kazuo, Murata, Akihito
Format Journal Article
LanguageEnglish
Japanese
Published Japanese Society of Chemotherapy 1992
公益社団法人 日本化学療法学会
Subjects
MEPM
Meropenem
SM-7338
カルバペネム
Online AccessGet full text
ISSN0009-3165
1884-5894
DOI10.11250/chemotherapy1953.40.Supplement1_851

Cover

More Information
Summary:Meropenem (MEPM) was adiministered by intravenous drip infusion at 500 mg b.i.d. to four patients with respiratory tract infections for 3 to 14 days. The clinical responses were good in two and poor in one of the three cases of bacterial pneumonia and poor in one case of infected lung cancer. One strain each of Haemophilus influenzae and Streptococcus pneumoniae was eradicated by administration of MEPM. Apart from one case of transiently and slightly elevated GOT and GTP, no adverse reaction or abnormal laboratory findings were noted following adminstration of MEPM.
ISSN:0009-3165
1884-5894
DOI:10.11250/chemotherapy1953.40.Supplement1_851